H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics to $11 from $60 and keeps a Buy rating on the shares post the Q2 report. The analyst’s medium-term revenue forecasts have been significantly decreased in order to reflect the lower priority on commercializing Igalmi in the institutional setting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BTAI:
- Biotech Alert: Searches spiking for these stocks today
- Largest borrow rate increases among liquid names
- Redfin upgraded, CSSE downgraded: Wall Street’s top analyst calls
- BioXcel Therapeutics price target lowered to $20 from $75 at Canaccord
- BioXcel Therapeutics price target lowered to $31 from $71 at Truist
